Obi Pharma Inc operates in the Commercial physical research sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Obi Pharma Inc with three other
companies in this sector in Taiwan:
Tpg Biologics Inc
sales of 48.22 million Taiwanese Dollars [US$1.61 million]
Taiwan Liposome Co Limited
(41.67 million Taiwanese Dollars [US$1.39 million]
of which 100%
was Biopharmaceutical), and
Taigen Biopharmaceuticals Holdings Ltd
(146.02 million Taiwanese Dollars [US$4.86 million]
of which 90%
was Medical Development).